Axilum Robotics Announces U.S. FDA 510(k) Clearance for TMS-Cobot
Axilum Robotics, specializing in the development of medical robots, announces that, 2 weeks after the CE mark, the Company has received 510(k) clearance from the U.S. Food and Drug Administration to market the TMS-Cobot TS MV, indicated for the spatial positioning and orientation of the treatment coil of the MagVenture TMS Therapy system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005667/en/
Axilum Robotics TMS-Cobot (Photo: Business Wire)
After having successfully developed and launched outside of the United States (OUS) the TMS-Robot, the first robot designed to assist health care professionals in delivering Transcranial Magnetic Stimulation (TMS), based on an invention of ICube laboratory in Strasbourg, Axilum Robotics has reinforced its expertise in medical robotics with the development of a new platform based on collaborative robot technology.
TMS-Cobot, the first medical device built on this platform, allows the company to offer an affordable and versatile system, thanks particularly to a proprietary optical tracking system, which allows the control in real time of the position, orientation and contact of the stimulation device, with patient head motion compensation.
The compatible MagVenture TMS Therapy System is indicated in the U.S. for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. It was FDA cleared for this use on July 31, 2015.
Axilum Robotics’ TMS-Cobot TS MV will be distributed in the U.S. by MagVenture Inc. who is also the distributor of the MagVenture TMS Therapy System.
Transcranial Magnetic Stimulation is a rapidly expanding, non-invasive neurostimulation technique, particularly in the U.S. where TMS has been covered by health insurance since 2012 and there is an increasing awareness of its current limitations when the coil is held manually or attached to a passive holder, requiring the patient to stay perfectly still. “TMS-Cobot will allow us to better address the needs of the TMS therapeutic market by providing an affordable solution to allow precise TMS delivery while relieving the operator from a demanding and time-consuming task and reducing the movement constraints on the patient. It is important for the user to maximize the chance to deliver the stimulation dose at the right location and our medical robots help make this possible!” explains Michel Berg, CEO of Axilum Robotics.
“We are very happy to partner with MagVenture Inc. who will distribute our device in the U.S. with its MagV TMS Therapy System. We are convinced that this robotized system represents a major step forward for the implementation of TMS” in the USA adds Michel Berg.
About Axilum Robotics
Axilum Robotics was founded in 2011 in Strasbourg, France, by a team of leading experts in medical robotics. The objective of the company is to provide researchers and health care professionals with robotic solutions to improve both technical medical procedures and medical resources management.
In 2013, the company launched the TMS-Robot OUS, the first CE marked medical robot specifically designed for Transcranial Magnetic Stimulation.
TMS is a non-invasive neurostimulation technique. Its approved and potential applications are numerous, ranging from neuroscience research to the treatment of drug resistant neurological or psychiatric diseases. The procedure is usually implemented manually or with a fixed stand supporting the coil.
Axilum Robotics has been ISO 13485 certified for its Quality Management System since 2013.
Beyond its activities in Transcranial Magnetic Stimulation, Axilum Robotics is member of a consortium engaged in the development of a device intended for blood brain barrier opening using ultrasound (3BOPUS, supported by National Research Agency) and member of a consortium for the development of a device for the treatment of bone metastases using ultrasound (UFOGUIDE, supported by French Unique Interministerial Fund).
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™24.4.2019 11:30:00 EEST | Tiedote
Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019. SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization. It is the intention of the Smart Pharma group to continue to incorporate Aenco’s blockchain technology into its pharmaceutical development and commercialization processes. Relying on intellectual property derived from the Smart-ACT™ platform, Smart Pharma’s in-house new and repurposed
Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases24.4.2019 11:30:00 EEST | Tiedote
Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005095/en/ (Photo: Business Wire) Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACTTM platform will initially focus on the screening drug molecules for orphan diseases or unmet medical needs. To date, SmartP has, under the recently established
Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 201924.4.2019 11:15:00 EEST | Tiedote
Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-negotiated transaction, repurchased all outstanding US$13,500,000 in aggregate principal amount of the 8.00 per cent. convertible bonds due 2019 (“Convertible Bonds”) from Peace Range Limited, a wholly owned subsidiary of Adamas Ping An Opportunities Fund LP, together with certain subscription right to subscribe up to the principal amount of the Bond at a US$12.17 (subject to adjustment) on or before December 17, 2019 (“Subscription Right”). The total consideration of the repurchase of the Convertible Bonds and the Subscription Right was US$13.6 million in cash, excluding accrued interest. The repurchase of the Convertible Bonds and Subscription Right was executed by Aptorum Investment Holding Limited, a wholly owned subsidiary
The Energy Efficient Mortgages Initiative is Defining the Future: a Greener Future24.4.2019 11:03:00 EEST | Tiedote
Today, the Energy Efficient Mortgages (EEM) Initiative is taking another important step toward its objective of delivering a standardised European framework and data collection architecture for energy efficient mortgages. The EEM Initiative is organising a series of high-profile EEM Initiative events in Riga, Latvia, gathering together relevant stakeholders from the financing and banking communities, property and construction sectors, as well as policymakers to discuss how to align market best practices and debate the next steps with a view to securing market development in relation to energy efficient mortgages, in line with the overall objectives of the Capital Markets Union (CMU). These events are being organised alongside the 29th ECBC Plenary Meeting, where the covered bond industry is celebrating another milestone in the form of the adoption of the Covered Bond Legislative Package (read more (link to be added) ). To recall, the objective of the Initiative is to stimulate and fina
Leading P&G Brands Including Pampers, Ariel and Herbal Essences Expand Leadership in Responsible Consumption24.4.2019 11:00:00 EEST | Tiedote
The Procter & Gamble Company (NYSE:PG) today detailed the roadmap and actions its leadership brands are taking to increase positive impact on society and the environment through its “Brand 2030” criteria. Today at the Sustainable Brands Paris conference, senior Company officials presented a forward-looking framework, including innovation strategies that will inspire and enable responsible consumption for the five billion consumers served by P&G each day. P&G leading brands including Pampers®, Ariel® and Herbal Essences® are progressing in adopting this framework with actions and commitments that will help accelerate sustainable lifestyles. “Consumers are no longer willing to compromise performance for living sustainably and they expect brands to take meaningful action in solving some of the most complex challenges facing the world,” said Marc Pritchard, P&G’s Chief Brand Officer. “This is why P&G is focused on reinventing marketing to use the reach and voice of our brands as a force fo
UNAOC and BMW Group Launch Search for Innovative Projects Promoting Intercultural Dialogue and Understanding24.4.2019 10:30:00 EEST | Tiedote
The United Nations Alliance of Civilizations (UNAOC) and the BMW Group launched the call for applications of the sixth edition of the Intercultural Innovation Award. Grassroots initiatives that encourage intercultural understanding through innovative methods, with the aim of alleviating identity-based conflicts around the world, are encouraged to apply online at interculturalinnovation.org. This year, the deadline for applications is 31 May, at 5:00 PM EDT. Following a competitive process, ten organizations will be selected to receive the Intercultural Innovation Award. Based on their needs, recipients will receive a monetary grant to help their projects expand and replicate (total funding available in 2019: USD 100,500). They will also benefit from a one-year mentoring program, which will include capacity-building training in a multitude of areas, from communications to fundraising and project management. Recipients of the Intercultural Innovation Award will also become members of Int
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme